Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5049993 | 0.92 | KDM4E (0.66) | KDM4EKMT2AHTTMAPK1TP53 | |
| SCHEMBL5042369 | 0.90 | KDM4E (0.51) | KDM4EKMT2AHTTMAPK1POLB | |
| SCHEMBL5048467 | 0.90 | MAPK1 (0.64) | KDM4EKMT2AHTTMAPK1TP53 | |
| SCHEMBL5034984 | 0.88 | KDM4E (0.54) | KDM4EKMT2AHTTMAPK1TP53 | |
| SCHEMBL5041958 | 0.88 | MAPK1 (0.65) | KDM4EKMT2AHTTMAPK1TP53 | |
| SCHEMBL5048285 | 0.85 | MAPK1 (0.58) | KDM4EKMT2AHTTMAPK1TP53 | |
| SCHEMBL5042023 | 0.85 | MAPK1 (0.64) | KDM4EKMT2AHTTMAPK1TP53 | |
| SCHEMBL5048323 | 0.84 | MAPK1 (0.57) | KDM4EKMT2AHTTMAPK1TP53 | |
| SCHEMBL5041939 | 0.84 | MAPK1 (0.59) | KDM4EKMT2AHTTMAPK1TP53 | |
| SCHEMBL5049998 | 0.83 | MAPK1 (0.55) | KDM4EKMT2AHTTMAPK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378417-B2 | Pyrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-27 | — | — | US | claimed |
| US-20050282827-A1 | Pyrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-22 | — | — | US | claimed |
| US-7378417-B2 | Pyrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050282827-A1 | Pyrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282827-A1 | Pyrazolo-pyrimidine derivatives | P2RX3, P2RX1, P2RX5 | KDM4E 3638/4885KMT2A 3706/4885HTT 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.